Neutral Alembic Pharma; target of Rs 930: Motilal Oswal

Motilal Oswal’s research report on Alembic Pharma Alembic Pharma (ALPM) delivered a better-than-expected performance in 4QFY25. A strong performance in export markets was offset partly by a muted show in…